You are here

EpiPens

Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi

Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi

Fierce Pharma

Flag link:

EpiPen litigation comes back to haunt Teva a decade after initial settlements

EpiPen litigation comes back to haunt Teva a decade after initial settlements

Fierce Pharma

Teva Pharmaceutical

Flag link:

Bryn advances anaphylaxis nasal spray after completing pivotal trial

Bryn advances anaphylaxis nasal spray after completing pivotal trial

Fierce Pharma

Flag link:

Aquestive's oral rival to EpiPen clears test on path to pivotal trial

Aquestive's oral rival to EpiPen clears test on path to pivotal trial

Fierce Pharma

Aquestive Therapeutics

clinical trials

ephinephrine oral film

Flag link:

Pfizer agrees to pay $345 mln to resolve EpiPen pricing lawsuit

Pfizer agrees to pay $345 mln to resolve EpiPen pricing lawsuit

Reuters

Flag link:

Sanofi looks to take Mylan to court, again, over EpiPen antitrust allegations

Sanofi looks to take Mylan to court, again, over EpiPen antitrust allegations

Fierce Pharma

Flag link:

FDA warns of premature EpiPen auto-injector activations

FDA warns of premature EpiPen auto-injector activations

Fierce Biotech

Flag link:

Pfizer may send EpiPen manufacturing to generics spinoff

Pfizer may send EpiPen manufacturing to generics spinoff

Biopharma Dive

Meridian Medical Technologies

Flag link:

Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger

Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger

Fierce Pharma

Flag link:

Health Canada to keep importing Kaleo's epinephrine shot amid shortages

Health Canada to keep importing Kaleo's epinephrine shot amid shortages

Yahoo/Reuters

epinephrine auto-injector

Flag link:

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Fierce Pharma

Adamis Pharmaceuticals

Flag link:

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

Endpoints

Flag link:

EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes

EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes

Business Insider

Meridian Medical Technologies

Flag link:

Sandoz launches EpiPen rival at $250 per two-pack

Sandoz launches EpiPen rival at $250 per two-pack

BioPharma Dive

Flag link:

Adamis stock surges on release of EpiPen alternative

Adamis stock surges on release of EpiPen alternative

Marketwatch

Flag link:

Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount

Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount

Fierce Pharma

Teva Pharmaceutical

Flag link:

Teva launches EpiPen generic at same price as Mylan's version

Teva launches EpiPen generic at same price as Mylan's version

Biopharma Dive

Teva Pharmaceutical

Flag link:

Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment

Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment

Fierce Pharma

Flag link:

Mylan secretly maneuvered to suppress evidence in EpiPen suit, plaintiffs say

Mylan secretly maneuvered to suppress evidence in EpiPen suit, plaintiffs say

Fierce Pharma

Flag link:

With EpiPen competitors bearing down, can Mylan maintain its lead?

With EpiPen competitors bearing down, can Mylan maintain its lead?

Fierce Pharma

ephinephrine autoinjectors

Flag link:

Pages